

Donna Rowen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8626010/publications.pdf>

Version: 2024-02-01

90
papers

3,629
citations

126708

33
h-index

149479

56
g-index

93
all docs

93
docs citations

93
times ranked

3673
citing authors

#	ARTICLE	IF	CITATIONS
1	A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. <i>European Journal of Health Economics</i> , 2010, 11, 215-225.	1.4	392
2	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. <i>Health Technology Assessment</i> , 2014, 18, 1-224.	1.3	276
3	Mapping to Obtain EQ-5D Utility Values for Use in NICE Health Technology Assessments. <i>Value in Health</i> , 2013, 16, 202-210.	0.1	202
4	Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 27.	1.0	144
5	Deriving a Preference-Based Measure for Cancer Using the EORTC QLQ-C30. <i>Value in Health</i> , 2011, 14, 721-731.	0.1	132
6	International Regulations and Recommendations for Utility Data for Health Technology Assessment. <i>Pharmacoeconomics</i> , 2017, 35, 11-19.	1.7	105
7	Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?. <i>Pharmacoeconomics</i> , 2020, 38, 325-340.	1.7	86
8	QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. <i>Quality of Life Research</i> , 2016, 25, 625-636.	1.5	83
9	A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models. <i>Pharmacoeconomics</i> , 2017, 35, 21-31.	1.7	79
10	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018, 36, 225-238.	1.7	77
11	A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. <i>Medical Decision Making</i> , 2015, 35, 328-340.	1.2	76
12	An Exploratory Study to Test the Impact on Three "Bolt-On" Items to the EQ-5D. <i>Value in Health</i> , 2015, 18, 52-60.	0.1	74
13	Estimating Preference-Based Single Index Measures for Dementia Using DEMQOL and DEMQOL-Proxy. <i>Value in Health</i> , 2012, 15, 346-356.	0.1	72
14	Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2. <i>Medical Care</i> , 2020, 58, 557-565.	1.1	66
15	An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 295-313.	1.0	63
16	Mapping onto Eq-5 D for patients in poor health. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 141.	1.0	61
17	Binary Choice Health State Valuation and Mode of Administration: Head-to-Head Comparison of Online and CAPI. <i>Value in Health</i> , 2013, 16, 104-113.	0.1	61
18	The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2017, 35, 33-41.	1.7	61

#	ARTICLE	IF	CITATIONS
19	Estimating the SF-6D Value Set for a Population-Based Sample of Brazilians. <i>Value in Health</i> , 2011, 14, S108-S114.	0.1	59
20	Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. <i>Quality of Life Research</i> , 2016, 25, 637-649.	1.5	58
21	The development of a QALY measure for epilepsy: NEWQOL-6D. <i>Epilepsy and Behavior</i> , 2012, 24, 36-43.	0.9	52
22	Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life. <i>Medical Decision Making</i> , 2016, 36, 210-222.	1.2	50
23	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. <i>Health Technology Assessment</i> , 2014, 18, vii-xxvi, 1-191.	1.3	47
24	Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?. <i>Value in Health</i> , 2019, 22, 62-68.	0.1	45
25	Comparison of Generic, Condition-Specific, and Mapped Health State Utility Values for Multiple Myeloma Cancer. <i>Value in Health</i> , 2012, 15, 1059-1068.	0.1	42
26	A Portuguese Value Set for the SF-6D. <i>Value in Health</i> , 2010, 13, 624-630.	0.1	41
27	From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 134.	1.0	40
28	Experience-based utility and own health state valuation for a health state classification system: why and how to do it. <i>European Journal of Health Economics</i> , 2018, 19, 881-891.	1.4	40
29	Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. <i>Value in Health</i> , 2021, 24, 812-821.	0.1	39
30	Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 140.	1.0	38
31	Improving the Measurement of QALYs in Dementia: Developing Patient- and Carer-Reported Health State Classification Systems Using Rasch Analysis. <i>Value in Health</i> , 2012, 15, 323-333.	0.1	37
32	Developing preference-based health measures: using Rasch analysis to generate health state values. <i>Quality of Life Research</i> , 2010, 19, 907-917.	1.5	36
33	It's All in the Name, or Is It? The Impact of Labeling on Health State Values. <i>Medical Decision Making</i> , 2012, 32, 31-40.	1.2	36
34	Estimating a Preference-Based Index from the Clinical Outcomes in Routine Evaluation "Outcome Measure (CORE-OM). <i>Medical Decision Making</i> , 2013, 33, 381-395.	1.2	36
35	Mapping Functions in Health-Related Quality of Life. <i>Medical Decision Making</i> , 2015, 35, 912-926.	1.2	35
36	Estimating a Dutch Value Set for the Pediatric Preference-Based CHU9D Using a Discrete Choice Experiment with Duration. <i>Value in Health</i> , 2018, 21, 1234-1242.	0.1	35

#	ARTICLE	IF	CITATIONS
37	Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. <i>Quality of Life Research</i> , 2017, 26, 1163-1176.	1.5	34
38	Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. <i>European Journal of Health Economics</i> , 2012, 13, 575-587.	1.4	32
39	Mapping the Functional Assessment of Cancer Therapy-General or -Colorectal to SF-6D in Chinese Patients with Colorectal Neoplasm. <i>Value in Health</i> , 2012, 15, 495-503.	0.1	31
40	U.K. utility weights for the <sc>EORTC QLQ-C30</sc>. <i>Health Economics (United Kingdom)</i> , 2019, 28, 1385-1401.	0.8	30
41	A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health. <i>Value in Health</i> , 2021, 24, 443-460.	0.1	29
42	Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index. <i>Value in Health</i> , 2021, 24, 281-290.	0.1	28
43	Comparison of General Population, Patient, and Carer Utility Values for Dementia Health States. <i>Medical Decision Making</i> , 2015, 35, 68-80.	1.2	27
44	Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 89-104.	1.0	27
45	Exploring the Consistency of the SF-6D. <i>Value in Health</i> , 2013, 16, 1023-1031.	0.1	26
46	A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents. <i>Value in Health</i> , 2020, 23, 907-917.	0.1	25
47	Development of a New Quality of Life Measure for Duchenne Muscular Dystrophy Using Mixed Methods. <i>Neurology</i> , 2021, 96, e2438-e2450.	1.5	24
48	Valuing child and adolescent health: a qualitative study on different perspectives and priorities taken by the adult general public. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 222.	1.0	24
49	Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D. <i>Value in Health</i> , 2017, 20, 687-693.	0.1	23
50	Deriving a Preference-Based Measure for Myelofibrosis from the EORTC QLQ-C30 and the MF-SAF. <i>Value in Health</i> , 2015, 18, 846-855.	0.1	21
51	The Use of Mapping to Estimate Health State Utility Values. <i>Pharmacoeconomics</i> , 2017, 35, 57-66.	1.7	21
52	Valuing states from multiple measures on the same visual analogue scale: a feasibility study. <i>Health Economics (United Kingdom)</i> , 2012, 21, 715-729.	0.8	19
53	Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire Scores in Patients with Colorectal Cancer. <i>Value in Health</i> , 2013, 16, 373-384.	0.1	18
54	Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 6.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Using a Discrete-Choice Experiment Involving Cost to Value a Classification System Measuring the Quality-of-Life Impact of Self-Management for Diabetes. <i>Value in Health</i> , 2018, 21, 69-77.	0.1	17
56	Estimating a Preference-Based Single Index Measuring the Quality-of-Life Impact of Self-Management for Diabetes. <i>Medical Decision Making</i> , 2018, 38, 699-707.	1.2	16
57	The impact of adding an extra dimension to a preference-based measure. <i>Social Science and Medicine</i> , 2011, 73, 245-253.	1.8	15
58	Do Portuguese and UK health state values differ across valuation methods?. <i>Quality of Life Research</i> , 2011, 20, 609-619.	1.5	15
59	Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff. <i>Pharmacoeconomics</i> , 2020, 38, 871-881.	1.7	15
60	What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the development of the EQ-HWB?. <i>European Journal of Health Economics</i> , 2021, 22, 1067-1081.	1.4	15
61	Developing a dementia-specific preference-based quality of life measure (AD-5D) in Australia: a valuation study protocol. <i>BMJ Open</i> , 2018, 8, e018996.	0.8	14
62	Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. <i>Epilepsy and Behavior</i> , 2014, 36, 12-17.	0.9	13
63	PROM Validation Using Paper-Based or Online Surveys: Data Collection Methods Affect the Sociodemographic and Health Profile of the Sample. <i>Value in Health</i> , 2019, 22, 845-850.	0.1	13
64	Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL. <i>Value in Health</i> , 2021, 24, 1499-1510.	0.1	13
65	Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1037.	1.2	12
66	Producing a preference-based quality of life measure for people with Duchenne muscular dystrophy: a mixed-methods study protocol. <i>BMJ Open</i> , 2019, 9, e023685.	0.8	11
67	Discrete choice experiments or best-worst scaling? A qualitative study to determine the suitability of preference elicitation tasks in research with children and young people. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 26.	0.9	11
68	Estimating informal care inputs associated with EQ-5D for use in economic evaluation. <i>European Journal of Health Economics</i> , 2016, 17, 733-744.	1.4	10
69	Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses. <i>Heart Failure Reviews</i> , 2019, 24, 549-563.	1.7	10
70	Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?. <i>Value in Health</i> , 2022, 25, 1196-1204.	0.1	10
71	Common Scale Valuations across Different Preference-Based Measures. <i>Medical Decision Making</i> , 2013, 33, 839-852.	1.2	9
72	Estimating an exchange rate between the EQ-5D-3L and ASCOT. <i>European Journal of Health Economics</i> , 2018, 19, 653-661.	1.4	8

#	ARTICLE	IF	CITATIONS
73	A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets. <i>Pharmacoeconomics</i> , 2022, 40, 863-882.	1.7	8
74	Valuing quality in mental healthcare: A discrete choice experiment eliciting preferences from mental healthcare service users, mental healthcare professionals and the general population. <i>Social Science and Medicine</i> , 2022, 301, 114885.	1.8	7
75	Deriving a preference-based utility measure for cancer patients from the European Organisation for the Research and Treatment of Cancer's Quality of Life Questionnaire C30: a confirmatory versus exploratory approach. <i>Patient Related Outcome Measures</i> , 2014, 5, 119.	0.7	6
76	Selection and validation of a classification system for a child-centred preference-based measure of oral health-related quality of life specific to dental caries. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 105.	0.9	6
77	Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults. <i>Pharmacoeconomics</i> , 2022, 40, 479-488.	1.7	6
78	Reducing the Floor Effect in the SF-6D: A Feasibility Study. <i>Applied Research in Quality of Life</i> , 2012, 7, 193-208.	1.4	5
79	Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 597-614.	1.0	5
80	Measuring What Matters: Little Evidence Supporting the Content Validity of EQ-5D in People with Duchenne Muscular Dystrophy and Their Caregivers. <i>Medical Decision Making</i> , 2022, 42, 139-140.	1.2	5
81	Valuation of preference-based measures: can existing preference data be used to select a smaller sample of health states?. <i>European Journal of Health Economics</i> , 2019, 20, 245-255.	1.4	4
82	Assessment of the psychometric properties and refinement of the Health and Self-Management in Diabetes Questionnaire (HASMID). <i>Health and Quality of Life Outcomes</i> , 2020, 18, 59.	1.0	4
83	What Matters for Evaluating the Quality of Mental Healthcare? Identifying Important Aspects in Qualitative Focus Groups with Service Users and Frontline Mental Health Professionals. <i>Patient</i> , 2022, 15, 669-678.	1.1	4
84	Androgen Deprivation Therapy for Prostate Cancer Prevention: What Impact Do Related Adverse Events Have on Quality of Life?. <i>Health Outcomes Research in Medicine</i> , 2012, 3, e169-e180.	0.6	3
85	Transforming challenges into opportunities: conducting health preference research during the COVID-19 pandemic and beyond. <i>Quality of Life Research</i> , 2022, 31, 1191-1198.	1.5	1
86	A Discrete Choice Experiment to Elicit General Population Preferences Around the Factors Influencing the Choice to Make Clinical Negligence Claims. <i>Value in Health</i> , 2022, 25, 1404-1415.	0.1	1
87	Response to Comments on Mulhern et al., "Improving the Measurement of QALYs in Dementia: Developing Patient- and Carer-Reported Health State Classification Systems Using Rasch Analysis". <i>Value in Health</i> , 2012, 15, 787-788.	0.1	0
88	Development of a preference-based heart disease-specific health state classification system using MacNew heart disease-related quality of life instrument. <i>Quality of Life Research</i> , 2022, 31, 257-268.	1.5	0
89	Preference-Weighted Health States. , 2014, , 5028-5030.		0
90	Preference-Based Measures of Health-Related Quality of Life. , 2014, , 5026-5028.		0